Vor Biopharma Inc.
VORNASDAQHealthcare● Active
$13.26
$-0.03(-0.23%)
Market Cap$90882794
P/E Ratio—
52W High$65.8
52W Low$3.62
Vor Biopharma Inc. (VOR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VOR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.73
Est. -$0.75 · +2.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
VOR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.70 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.75 | -$0.73 | +2.7% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$1.14 | $44.50 | +4003.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$3.06 | -$3.33 | -8.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$11.40 | -$43.60 | -282.5% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.25 | -$0.26 | -4.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.34 | -$0.44 | -29.4% | — | — | — |
| — Q4 FY2024 | Nov 7, 2024 | -$0.40 | -$0.40 | +0.0% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.73
EPS Est.
-$0.75
EPS Surpr.
+2.7%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
$44.50
EPS Est.
-$1.14
EPS Surpr.
+4003.5%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$3.33
EPS Est.
-$3.06
EPS Surpr.
-8.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$43.60
EPS Est.
-$11.40
EPS Surpr.
-282.5%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.25
EPS Surpr.
-4.0%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.34
EPS Surpr.
-29.4%
Revenue
—
Q4 FY2024
Nov 7, 2024
EPS Actual
-$0.40
EPS Est.
-$0.40
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-0.72 | $-0.72 | $-0.72 | 1 |
| Q3 FY2029 | $-0.78 | $-0.78 | $-0.78 | 1 |
| Q2 FY2029 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Q1 FY2029 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Q4 FY2028 | $-0.89 | $-0.89 | $-0.89 | 1 |
| Q3 FY2028 | $-0.87 | $-0.87 | $-0.87 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +2.7% | $16.47 | $15.91 | -3.40% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +4003.5% | $14.48 | $14.70 | +1.52% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -8.8% | $10.06 | $9.75 | -3.08% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -282.5% | $39.80 | $33.20 | -16.58% |
| ▼ Q2 FY2025 | May 14, 2025 | -4.0% | $3.20 | $3.42 | +6.87% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -29.4% | $16.88 | $17.04 | +0.95% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +0.0% | $17.20 | $16.68 | -3.02% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +0.0% | $16.40 | $16.62 | +1.34% |
Q2 FY2026-3.40%
Report Date
May 13, 2026
EPS Beat/Miss
+2.7%
Price Before
$16.47
Price After
$15.91
Q1 FY2026+1.52%
Report Date
Mar 30, 2026
EPS Beat/Miss
+4003.5%
Price Before
$14.48
Price After
$14.70
Q4 FY2025-3.08%
Report Date
Nov 13, 2025
EPS Beat/Miss
-8.8%
Price Before
$10.06
Price After
$9.75
Q3 FY2025-16.58%
Report Date
Aug 12, 2025
EPS Beat/Miss
-282.5%
Price Before
$39.80
Price After
$33.20
Q2 FY2025+6.87%
Report Date
May 14, 2025
EPS Beat/Miss
-4.0%
Price Before
$3.20
Price After
$3.42
Q1 FY2025+0.95%
Report Date
Mar 20, 2025
EPS Beat/Miss
-29.4%
Price Before
$16.88
Price After
$17.04
Q4 FY2024-3.02%
Report Date
Nov 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$17.20
Price After
$16.68
Q3 FY2024+1.34%
Report Date
Aug 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$16.40
Price After
$16.62
Avg Beat Reaction-0.89%
Avg Miss Reaction-2.96%
Beat Rate4 / 8 quarters
Largest Move-16.58% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VOR ends December
Vor Biopharma Inc. (VOR) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.73 — beating the analyst consensus of $-0.75 by +2.7%. VOR has beaten EPS estimates for 2 consecutive quarters. The next VOR earnings date is expected around September 1, 2026.
Each quarter, investors track VOR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VOR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VOR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VOR earnings · 5 questionsVor Biopharma Inc.'s next earnings report is expected around September 1, 2026. VOR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VOR historically reports after market close (AMC).
VOR earnings datewhen is VOR earningsVOR next earnings datewhen does VOR report earningsVOR earnings calendar
▸ Source: FMP · Vor Biopharma Inc. SEC filings · US GAAP · Vor Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026